Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 264

1.

Risk Communication and the Pharmaceutical Industry: what is the reality?

Edwards B, Chakraborty S.

Drug Saf. 2012 Nov 1;35(11):1027-40. doi: 10.2165/11635220-000000000-00000.

PMID:
23061779
[PubMed - indexed for MEDLINE]
2.

Challenges of drug risk communications in the Philippines.

Hartigan-Go K.

Drug Saf. 2012 Nov 1;35(11):995-1004. doi: 10.2165/11635920-000000000-00000.

PMID:
23061777
[PubMed - indexed for MEDLINE]
3.

Risk perception and communication in sub-Saharan Africa.

Dodoo A, Hugman B.

Drug Saf. 2012 Nov 1;35(11):1041-52. doi: 10.2165/11636270-000000000-00000. Review.

PMID:
23061780
[PubMed - indexed for MEDLINE]
4.

Protecting the people?: risk communication and the chequered history and performance of bureaucracy.

Hugman B.

Drug Saf. 2012 Nov 1;35(11):1005-25. doi: 10.2165/11635210-000000000-00000.

PMID:
23061778
[PubMed - indexed for MEDLINE]
5.

Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.

Borg JJ, Aislaitner G, Pirozynski M, Mifsud S.

Drug Saf. 2011 Mar 1;34(3):187-97. doi: 10.2165/11586620-000000000-00000. Review.

PMID:
21332243
[PubMed - indexed for MEDLINE]
6.

Adverse drug reactions: when the risk becomes a reality for patients.

Cox AR, Butt TF.

Drug Saf. 2012 Nov 1;35(11):977-81. doi: 10.2165/11636140-000000000-00000.

PMID:
23061775
[PubMed - indexed for MEDLINE]
7.

Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

Hartford CG, Petchel KS, Mickail H, Perez-Gutthann S, McHale M, Grana JM, Marquez P.

Drug Saf. 2006;29(8):657-73. Review.

PMID:
16872240
[PubMed - indexed for MEDLINE]
8.

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.

Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC.

Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200. Review.

PMID:
21545758
[PubMed - indexed for MEDLINE]
Free Article
9.

Risk management frameworks for human health and environmental risks.

Jardine C, Hrudey S, Shortreed J, Craig L, Krewski D, Furgal C, McColl S.

J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. Review.

PMID:
14698953
[PubMed - indexed for MEDLINE]
10.

A risk-based approach to scheduling audits.

Rönninger S, Holmes M.

PDA J Pharm Sci Technol. 2009 Nov-Dec;63(6):575-88.

PMID:
20169864
[PubMed - indexed for MEDLINE]
11.

Issues with regulatory pharmacovigilance in East European countries: the industry perspective.

Hanzl-Dujmović I, Sulić-Milisić Z, Staresinić-Sernhorst I.

Toxicol Lett. 2007 Feb 5;168(3):228-35. Epub 2006 Nov 16. Review.

PMID:
17161561
[PubMed - indexed for MEDLINE]
12.

Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.

Arnardottir AH, Haaijer-Ruskamp FM, Straus SM, de Graeff PA, Mol PG.

Drug Saf. 2011 Nov 1;34(11):1101-14. doi: 10.2165/11592060-000000000-00000.

PMID:
21981437
[PubMed - indexed for MEDLINE]
13.

CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.

Tsintis P, La Mache E.

Drug Saf. 2004;27(8):509-17. Review.

PMID:
15154824
[PubMed - indexed for MEDLINE]
14.

Impact of safety-related regulatory action on clinical practice: a systematic review.

Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, Mol PG.

Drug Saf. 2012 May 1;35(5):373-85. doi: 10.2165/11599100-000000000-00000. Review.

PMID:
22480319
[PubMed - indexed for MEDLINE]
15.

How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.

Fleuranceau-Morel P.

Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):37-44.

PMID:
11998550
[PubMed - indexed for MEDLINE]
16.

Managing the interface with marketing to improve delivery of pharmacovigilance within the pharmaceutical industry.

Edwards B.

Drug Saf. 2004;27(8):609-17. Review.

PMID:
15154832
[PubMed - indexed for MEDLINE]
17.
18.

Communication about results of comparative effectiveness studies: a pharmaceutical industry view.

Perfetto EM, Bailey JE Jr, Gans-Brangs KR, Romano SJ, Rosenthal NR, Willke RJ.

Health Aff (Millwood). 2012 Oct;31(10):2213-9. doi: 10.1377/hlthaff.2012.0745.

PMID:
23048099
[PubMed - indexed for MEDLINE]
19.

The Internet and drug safety: what are the implications for pharmacovigilance?

Cobert B, Silvey J.

Drug Saf. 1999 Feb;20(2):95-107. Review.

PMID:
10082068
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk